Pharma

Pharma

2 FDA citations trouble Hengrui, Elevar’s liver cancer combo

Following resolution of the problem cited in the CRL, investors questioned why the FDA issued a swift rejection instead of waiting for the PDUFA date.

Angus Liu Jul 28, 2026 3:02pm

J&J proposes $5.5B deal to resolve 76,000 ovarian cancer claims

Jul 28, 2026 11:26am

The CSO Model Is Endangered Heres How Contract Field Organizations Must Evolve to Survive

The CSO Model Is Endangered. Here’s How to Evolve.

Brought to you by Mix Talent

Regulatory tracker: MannKind's edema autoinjector nets FDA nod

Jul 28, 2026 10:20am

Designing an agentic, future‑ready tech roadmap for emerging pharma

Brought to you by ZS

GSK CEO targets mature products, procurement for cost savings

Jul 28, 2026 9:45am